Subject: Nubeqa 3147-A SGM P2022a
Policy:
I. INDICATIONS
The indications below including FDA-approved indications and
compendial uses are considered a covered benefit provided
that all the approval criteria are met and the member has no
exclusions to the prescribed therapy.
FDA-Approved Indications
1. Nubeqa is indicated for the treatment of patients with non-
metastatic castration-resistant prostate cancer.
2. Nubeqa is indicated for the treatment of adult patients with
metastatic hormone-sensitive prostate cancer (mHSPC) in
combination with docetaxel.
All other indications are considered
experimental/investigational and not medically necessary.
II. EXCLUSIONS
Coverage will not be provided if the requested medication is
used in combination with a second-generation oral anti-
androgen (e.g., apalutamide [Erleada]) or an oral androgen
metabolism inhibitor (e.g., abiraterone acetate [Zytiga]).
III. CRITERIA FOR INITIAL APPROVAL
Prostate Cancer
Authorization of 12 months may be granted when either of the
following criteria are met:
1. The member has non-metastatic castration-resistant
prostate cancer and the member has had a bilateral
orchiectomy or will be using the requested medication in
combination with a GnRH analog.
2. The member has metastatic hormone-sensitive prostate
cancer and meets both of the following criteria:
i. The requested drug will be used in combination with
docetaxel
ii. The member has had a bilateral orchiectomy or will be
using the requested medication in combination with a
GnRH analog.
IV. CONTINUATION OF THERAPY
Authorization of 12 months may be granted for continued
treatment in members requesting reauthorization for an
indication listed in Section III when there is no evidence of
unacceptable toxicity or disease progression while on the
current regimen.
Place of Service:
Outpatient
The above policy is based on the following references:
- Nubeqa [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals Inc.; August 2022.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
December 29, 2022
